- Home
- PMVP vs GANX Comparison
PMVP vs GANX Comparison
Compare PMVP & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMVP
- GANX
- Stock Information
- Founded
- PMVP 2013
- GANX 2017
- Country
- PMVP United States
- GANX United States
- Employees
- PMVP N/A
- GANX N/A
- Industry
- PMVP Medicinal Chemicals and Botanical Products
- GANX Biotechnology: Pharmaceutical Preparations
- Sector
- PMVP Health Care
- GANX Health Care
- Exchange
- PMVP Nasdaq
- GANX Nasdaq
- Market Cap
- PMVP 62.3M
- GANX 51.8M
- IPO Year
- PMVP 2020
- GANX 2021
- Fundamental
- Price
- PMVP $1.48
- GANX $1.48
- Analyst Decision
- PMVP Strong Buy
- GANX Strong Buy
- Analyst Count
- PMVP 1
- GANX 5
- Target Price
- PMVP $5.00
- GANX $8.20
- AVG Volume (30 Days)
- PMVP 293.0K
- GANX 283.4K
- Earning Date
- PMVP 08-07-2025
- GANX 08-19-2025
- Dividend Yield
- PMVP N/A
- GANX N/A
- EPS Growth
- PMVP N/A
- GANX N/A
- EPS
- PMVP N/A
- GANX N/A
- Revenue
- PMVP N/A
- GANX N/A
- Revenue This Year
- PMVP N/A
- GANX N/A
- Revenue Next Year
- PMVP N/A
- GANX N/A
- P/E Ratio
- PMVP N/A
- GANX N/A
- Revenue Growth
- PMVP N/A
- GANX N/A
- 52 Week Low
- PMVP $0.81
- GANX $0.89
- 52 Week High
- PMVP $1.82
- GANX $3.19
- Technical
- Relative Strength Index (RSI)
- PMVP 61.82
- GANX 41.72
- Support Level
- PMVP $1.39
- GANX $1.41
- Resistance Level
- PMVP $1.55
- GANX $1.68
- Average True Range (ATR)
- PMVP 0.09
- GANX 0.12
- MACD
- PMVP -0.00
- GANX -0.00
- Stochastic Oscillator
- PMVP 75.00
- GANX 14.29
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a biotechnology company developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, lysosomal storage disorders, central nervous system disorders, metabolic disorders, and oncology. The company's clinical-stage product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson's disease. The company uses its computational target and drug discovery platform, Magellan, to discover novel allosteric binding sites on proteins implicated in disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Geographically, the company operates in Switzerland, Spain, the United States, and Australia.